Chemo Fog

1. Front Matter

   Pages i-xxi

   PDF

2. Short Introduction and History

   • Robert B. Raffa

   Pages 1-10

3. Patient’s Perspective

   • Robert B. Raffa, Kathleen J. Martin

   Pages 11-12

4. Oncology Nurse’s Perspective

   • Jamie S. Myers

   Pages 13-18

5. Oncology Pharmacist’s Perspective

   • Rachel Clark-Vetri

   Pages 19-20

6. The Impact of Chemo Brain on the Patient with a High-Grade Glioma

   • Michele R. Lucas

   Pages 21-25

7. Neurocognitive Effects of Childhood Cancer Treatment

   • Jennifer Costa

   Pages 26-32

8. The Economic Burden

   • Albert I. Wertheimer

   Pages 33-36

9. Designing Conceptual Model-Based Research in Chemotherapy-Related Changes in Cognitive Function

   • Lisa M. Hess

   Pages 37-54

10. Neuropsychologic Testing for Chemotherapy-Related Cognitive Impairment

    • Jamie S. Myers

    Pages 55-69

11. Imaging as a Means of Studying Chemotherapy-Related Cognitive Impairment

    • Robert B. Raffa

    Pages 70-76

12. Chemotherapy Associated Central Nervous System Damage

    • Jörg Dietrich

    Pages 77-85

13. Is Systemic Anti-Cancer Therapy Neurotoxic? Does Chemo Brain Exist? And Should We Rename It?

    • Sophie Taillibert

    Pages 86-95

14. Evaluation of Multiple Neurotoxic Outcomes in Cancer Chemotherapy

    • Bernard Weiss

    Pages 96-112

15. Chemotherapy-Related Visual System Toxicity

    • Robert B. Raffa

    Pages 113-118

16. The Possible Role of Cytokines in Chemotherapy-Induced Cognitive Deficits

    • Jamie S. Myers

    Pages 119-123

17. Pharmacokinetics of Anti-Cancer Drugs Used in Breast Cancer Chemotherapy

    • Swati Nagar

    Pages 124-132

18. Combination Analysis

    • Ronald J. Tallarida

    Pages 133-137

19. Animal Models

    • Ellen A. Walker

    Pages 138-146

20. Chemo Brain (Chemo Fog) as a Potential Side Effect of Doxorubicin Administration: Role of Cytokine-Induced, Oxidative/Nitrosative Stress in Cognitive Dysfunction

    • Christopher D. Aluise, Rukhsana Sultana, Jitbangjong Tangpong, Mary Vore, Daret St. Clair, Jeffrey A. Moscow et al.

    Pages 147-156

Cancer patients have benefitted greatly from recent advances in the drugs, dose regimens, and combinations used to treat their primary tumor and for the treatment or prevention of spread of their disease. Due to the advances in chemotherapy and other aspects of prevention, early detection, and treatment modalities, an increasing percentage of patients are surviving the disease. For some types of cancer, the majority of patients live decades beyond their diagnosis. For this they are forever thankful and appreciative of the drugs that helped lead to this increased survival rate. But no drug is devoid of adverse effects. This also applies to chemotherapeutic agents. The acute cytotoxic effects of these agents are well known––indeed are often required for their therapeutic benefit. The chronic adverse effects are varied and in some cases less well known. With the increase in survival rates, there has emerged a new awareness of these chronic adverse effects.

• Cancer
• Chemo
• Fog
• Raffa
• Tallarida
• imaging

• Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, USA

  Robert B. Raffa

• Department of Pharmacology, Temple University School of Medicine, Phhiladelphia, USA

  Ronald J. Tallarida

ROBERT B. RAFFA, PhD, is Professor of Pharmacology and Chair of the Department of Pharmaceutical Sciences at Temple University School of Pharmacy in Philadelphia, Pennslyvania. He holds B Chem E and BS degrees in Chemical Engineering and Physiological Psychology, MS degrees in Biomedical Engineering and Toxicology, and a PhD in Pharmacology. He is the co-author or editor of several books on pharmacology and thermodynamics and over 200 articles in refereed journals, and is active in NIH-funded research, editorial, and professional society activities. Dr. Raffa became co-founder and president of the Forget-Me-Not Foundation in 2009. RONALD J. TALLAR IDA, PhD, is a Professor of Pharmacology at Temple University School of Medicine. He has BS and MS degrees in physics/mathematics from Drexel University and a PhD in pharmacology. His work, primarily concerned with quantitative aspects of pharmacology, is represented in more than 250 published works that include eight books he has authored or co-authored. Dr. Tallarida currently teaches, serves on editorial advisory boards, conducts NIH-funded research, and is active in professional societies. Dr. Tallarida became co-founder and Vice-president of the Forget-Me-Not Foundation in 2009.

Policies and ethics